Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022年9月2日 - 9:00PM
Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or
“Viridian”), a biotechnology company advancing new treatments for
patients suffering from serious diseases but underserved by current
therapies, today announced that a majority of the independent
directors serving on the Compensation Committee of the Company’s
Board of Directors approved the grant of stock options to purchase
an aggregate of 103,000 shares of the Company’s common stock to
three new employees (the “Inducement Grants”) on September 1, 2022
(the “Grant Date”). The Inducement Grants have been granted outside
of the Company’s Amended and Restated 2016 Equity Incentive Plan
(the “Plan”) but remain subject to the terms and conditions of such
Plan. The Inducement Grants were granted as an inducement material
to these individuals entering into employment with Viridian in
accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grants have an exercise price per share that is
equal to the closing price of Viridian’s common stock on the Grant
Date. The Inducement Grants will vest over a four-year period, with
25% of the shares vesting on the one-year anniversary of the
employee’s start date, and thereafter the remainder of the shares
vest in 36 equal monthly installments, subject to continued
employment through the applicable vesting dates.
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company advancing
new treatments for patients suffering from serious diseases
underserved by current therapies. Viridian’s most advanced program,
VRDN-001, is a differentiated monoclonal antibody targeting
insulin-like growth factor-1 receptor (IGF-1R), a clinically and
commercially validated target for the treatment of thyroid eye
disease (TED). VRDN-002 is a distinct anti-IGF-1R antibody and
incorporates half-life extension technology. VRDN-003 is an
extended half-life version of VRDN-001. Both VRDN-002 and VRDN-003
are designed for administration as convenient, low-volume,
subcutaneous injections. TED is a debilitating autoimmune
disease that causes inflammation and fibrosis within the orbit of
the eye which can cause double vision, pain, and potential
blindness. Viridian is based in Waltham, Massachusetts.
Investor and Media ContactJohn JordanViridian
TherapeuticsVice President, Investor Relations& Corporate
Communications617-272-4691IR@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
過去 株価チャート
から 6 2024 まで 7 2024
Viridian Therapeutics (NASDAQ:VRDN)
過去 株価チャート
から 7 2023 まで 7 2024